Misconception: You Can’t Have Liver Disease With Normal Liver Chemistries
Zurabi Lominadze, Eric R. Kallwitz – 6 November 2018
Pro: Use of Hepatitis C Virus–Positive Donors Should Be Considered Standard of Care
William A. Werbel, Christine M. Durand – 6 November 2018
A Regulatory Role of Apoptosis Antagonizing Transcription Factor in the Pathogenesis of Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma
Divya P. Kumar, Prasanna K. Santhekadur, Mulugeta Seneshaw, Faridoddin Mirshahi, Cora Uram‐Tuculescu, Arun J. Sanyal – 5 November 2018 – Hepatocellular carcinoma (HCC) is increasing as a cause of liver‐related mortality largely because of the growing burden of nonalcoholic steatohepatitis (NASH). The mechanisms of HCC development in nonalcoholic fatty liver disease (NAFLD) are incompletely understood. We initially identified apoptosis antagonizing transcription factor (AATF) to be associated with HCC in a mouse model of NASH that develops HCC without the addition of specific carcinogens.
Immunosuppression Minimization Trials in Liver Transplantation: Can We Predict Humoral Response to Assess Eligibility?
Magdalena Meszaros, Jose Ursic‐Bedoya, Stéphanie Faure, Georges‐Philippe Pageaux – 5 November 2018
Letter to the Editor: Confirmation of the Optimization to Prevent the First Esophageal Variceal Bleeding?
Xinwen Yan, Ziyuan Zou, Xun Li, Xiaolong Qi – 4 November 2018
Highly Diverse Hepatitis C Strains Detected in Sub‐Saharan Africa Have Unknown Susceptibility to Direct‐Acting Antiviral Treatments
Chris Davis, George S. Mgomella, Ana da Silva Filipe, Eric H. Frost, Genevieve Giroux, Joseph Hughes, Catherine Hogan, Pontiano Kaleebu, Gershim Asiki, John McLauchlan, Marc Niebel, Ponsiano Ocama, Cristina Pomila, Oliver G. Pybus, Jacques Pépin, Peter Simmonds, Joshua B. Singer, Vattipally B. Sreenu, Clara Wekesa, Elizabeth H. Young, Donald G. Murphy, Manj Sandhu, Emma C.
A Pathophysiologic Approach Combining Genetics and Insulin Resistance to Predict the Severity of Nonalcoholic Fatty Liver Disease
Christopher J. Danford, Margery A. Connelly, Irina Shalaurova, Misung Kim, Mark A. Herman, Imad Nasser, James D. Otvos, Nezam H. Afdhal, Z. Gordon Jiang, Michelle Lai – 1 November 2018 – Nonalcoholic fatty liver disease (NAFLD) is a complex disease dictated by both genetic and environmental factors. While insulin resistance (IR) is a key pathogenic driver, two common genetic variants in patatin‐like phospholipase domain containing 3 (PNPLA3) and transmembrane 6 superfamily member 2 (TM6SF2) also impart significant risk for disease progression.
Challenges and Opportunities in the Clinical Development of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma
Michael J. Flynn, Anwar A. Sayed, Rohini Sharma, Abdul Siddique, David J. Pinato – 1 November 2018 – After a decade of stagnation in drug development, therapeutic reversal of immune‐exhaustion with immune checkpoint inhibitors (ICPIs) has been shown to be effective in advanced hepatocellular carcinoma (HCC). The clinical development of novel ICPIs continues at a rapid pace, with more than 50 clinical trials of immunotherapeutic agents registered as of May 2018 for this indication.
Surgical Resection Versus Transarterial Chemoembolization for Intermediate Stage Hepatocellular Carcinoma (BCLC‐B): An Unsolved Question
Ismail Labgaa, Nicolas Demartines, Emmanuel Melloul – 1 November 2018